OncoMatch/Clinical Trials/NCT05475171
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Is NCT05475171 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lorigerlimab for metastatic cancer.
Treatment: Lorigerlimab — To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Cervical Cancer
Disease stage
Metastatic disease required
recurrent, metastatic, or persistent cervical cancer; Not amenable to curative treatment (e.g. surgery and/or radiation); Measurable disease by RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
Exception: except when used with concurrent radiation therapy
Prior systemic chemotherapy except when used with concurrent radiation therapy
Cannot have received: immune checkpoint inhibitor
Previous immune checkpoint inhibitor therapy or cytokines
Lab requirements
Blood counts
Hemoglobin ≥8.0 g/dL; ANC > 1000/mm3; Platelet count ≥100 x 10^9/L (>75,000/mm3)
Kidney function
Measured or calculated creatinine clearance >40 mL/min (Cockcroft-Gault or 24-hour urine collection)
Liver function
Serum bilirubin ≤1.5 x ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN
Cardiac function
QTcF ≤ 470 within 12 months from first dose of study intervention; no NYHA Class III/IV CHF, unstable angina, MI, CVA, or arrhythmia with hemodynamic instability (medically controlled arrhythmia permitted)
Adequate normal organ and marrow function as defined below. ... QTcF > 470 within 12 months from first dose of study intervention, including New York Heart Association (NYHA) Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular event, or cardiac arrhythmia associated with hemodynamic instability. Note: medically controlled arrhythmia would be permitted.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify